Tiotropium

Prescription ·Strong evidence ·Reviewed May 2026

A long-acting muscarinic antagonist (LAMA/long-acting anticholinergic) that is a first-line maintenance bronchodilator for COPD and an add-on controller for moderate-to-severe asthma. Provides sustained 24-hour bronchodilation with once-daily dosing. In COPD, tiotropium reduces exacerbations, improves lung function, quality of life, and exercise tolerance. In asthma, it is used as add-on therapy when ICS/LABA combinations are insufficient.

What it's good for
  • First-line maintenance bronchodilator for COPD
  • Reduces COPD exacerbation frequency3,8
  • Improves FEV1 and exercise tolerance in COPD3,8
  • Add-on controller for moderate-to-severe persistent asthma
  • Once-daily dosing for patient convenience
What to watch for
  • Dry mouth (most common anticholinergic effect)
  • Constipation
  • Urinary retention
  • Known hypersensitivity to tiotropium or ipratropium (same class)1,2
  • Known hypersensitivity to atropine or atropine derivatives

The bottom line

Evidence rating strong. Most-documented uses: first-line maintenance bronchodilator for copd, reduces copd exacerbation frequency, improves fev1 and exercise tolerance in copd. 10 sources indexed (2014–2021), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Competitively and reversibly blocks muscarinic M3 receptors on airway smooth muscle and submucosal glands. Acetylcholine released from parasympathetic vagal nerve endings normally activates M3 receptors, causing bronchoconstriction and mucus secretion. Tiotropium's very slow dissociation from M3 receptors (kinetic selectivity, off-rate half-life of ~35 hours from M3 vs ~4 hours from M2) provides prolonged bronchodilation. This M3 selectivity avoids blocking presynaptic M2 autoreceptors, which would paradoxically increase acetylcholine release.

Class
Long-Acting Muscarinic Antagonist (LAMA)
Dosing

Dosing & protocol.

Common range
HandiHaler: 18 mcg (one capsule) inhaled once daily; Respimat: 2.5 mcg (2 puffs) once daily for COPD, 1.25 mcg (2 puffs) once daily for asthma (as prescribed by your physician)
Recommended form
Dry powder inhaler (HandiHaler) or soft mist inhaler (Respimat)

Delivered by inhalation. Oral bioavailability is extremely low (2-3%) due to quaternary ammonium structure. Systemic effects are minimal. Peak bronchodilation at 1-3 hours, duration >24 hours. Do not swallow capsules, they are for inhalation via HandiHaler device only.

Safety

Full safety detail.

Side effects

  • Dry mouth (most common anticholinergic effect)
  • Constipation
  • Urinary retention
  • Pharyngitis and upper respiratory tract infection
  • Sinusitis
  • Blurred vision (if sprayed into eyes)

Contraindications

  • Known hypersensitivity to tiotropium or ipratropium (same class)1,2
  • Known hypersensitivity to atropine or atropine derivatives
  • Not for acute bronchospasm relief (not a rescue medication)
  • Narrow-angle glaucoma (anticholinergic may worsen)
  • Urinary retention or bladder neck obstruction
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5
Keep exploring

Deep dives & adjacent profiles.

This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.

Use this with your stack

Tiotropium in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.